phrykt

Starling Oncology, Inc. (STLN): who owns it and who trades it

As of Nov 16, 2026, STLN insiders reported 12 open-market sales worth $14.2M and 17 purchases worth $2.9M in the last 12 months, with 18% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jorey Chernett (10% owner), with $11.4M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Starling Oncology

From the latest filings

Overall: about as much buying as selling. Congress mostly sold. Insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, STLN insiders reported $2.9M of open-market purchases and $14.2M of sales. 18% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$2.9M
17 trades, 1 people
Sales, 12 months
$14.2M
12 trades, 6 people
Sales under a 10b5-1 plan
18%
Share of sale value
Latest trade
Nov 9, 2026
Filed Nov 10, 2026

Purchases and sales by month

$11.4M$11.4MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 9, 2026Jorey Chernett10% ownerPurchase48,294$3.65$176KForm 4
Nov 6, 2026Jorey Chernett10% ownerSale2.85M$3.99$11.4MForm 4
Aug 21, 2026Brad HivelyDirectorSale plan298,853$6.51$1.9MForm 4
Aug 14, 2026Jorey Chernett10% ownerPurchase12,000$6.54$78.5KForm 4
Jul 21, 2026Jorey Chernett10% ownerPurchase18,000$5.27$94.9KForm 4
Jul 14, 2026Yale PodnosChief Medical OfficerSale plan5,478$6.35$34.8KForm 4
Jul 14, 2026Yale PodnosChief Medical OfficerSale plan17,974$6.43$116KForm 4
Jul 10, 2026Jorey Chernett10% ownerPurchase15,000$5.85$87.8KForm 4
Jun 23, 2026Jorey Chernett10% ownerPurchase18,000$5.02$90.4KForm 4
Jun 8, 2026Yale PodnosChief Medical OfficerSale plan23,451$5.38$126KForm 4
Jun 4, 2026Jorey Chernett10% ownerPurchase12,000$4.75$57KForm 4
May 20, 2026Jorey Chernett10% ownerPurchase33,500$4.07$136KForm 4
May 19, 2026Jorey Chernett10% ownerPurchase5,000$4.05$20.2KForm 4
May 19, 2026Jorey Chernett10% ownerPurchase30,000$4.09$123KForm 4
Apr 16, 2026Mohit KaushalDirectorSale plan38,433$3.50$135KForm 4
Apr 14, 2026Mohit KaushalDirectorSale plan57,286$3.50$201KForm 4
Apr 9, 2026Jorey Chernett10% ownerPurchase20,000$3.10$62KForm 4
Mar 27, 2026Jorey Chernett10% ownerPurchase27,429$2.96$81.2KForm 4
Mar 26, 2026Jorey Chernett10% ownerPurchase50,000$3.15$158KForm 4
Mar 24, 2026Jorey Chernett10% ownerPurchase125,000$3.11$389KForm 4
Mar 20, 2026Jorey Chernett10% ownerPurchase25,000$3.35$83.8KForm 4
Mar 17, 2026Jorey Chernett10% ownerPurchase75,000$3.42$256KForm 4
Mar 16, 2026Jorey Chernett10% ownerPurchase60,985$3.29$201KForm 4
Mar 13, 2026Jorey Chernett10% ownerPurchase263,000$2.92$768KForm 4
Jan 2, 2026Robert Ross CarterCFOSale247$3.56$879Form 4
Dec 15, 2025Brad HivelyDirectorSale13,333$3.77$50.3KForm 4
Nov 18, 2025Mark L PacalaDirectorSale46,630$4.00$187KForm 4
Nov 18, 2025Mark L PacalaDirectorSale2,160$4.00$8.6KForm 4
Nov 18, 2025Mark L PacalaDirectorSale1,210$4.00$4.8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jorey Chernett10% owner$2.9M$11.4MNov 9, 2026
Brad HivelyDirector–$2MAug 21, 2026
Mohit KaushalDirector–$335KApr 16, 2026
Yale PodnosChief Medical Officer–$277KJul 14, 2026
Mark L PacalaDirector–$200KNov 18, 2025
Robert Ross CarterChief Financial Officer–$879Jan 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

STLN short interest

Moderate short interest. 6.7% of STLN shares are sold short: about 1 share in 15. Over the last 6 reports the number of shares short went down 1%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 6.84M STLN shares were sold short, 6.7% of the shares outstanding, up 4.7% from the report before. At the average daily volume of 1.26M shares, buying them all back would take about 5.4 trading days (days to cover).

Shares short, % of all shares

6.71%Aug 14Oct 307.00%

Days to cover

5.4Aug 14Oct 307.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20266.84M6.71%+5%1.26M5.4
Oct 15, 20266.54M6.41%-4%1.16M5.6
Sep 30, 20266.79M6.67%-4%1.58M4.3
Sep 15, 20267.05M6.92%+3%959,3657.3
Aug 31, 20266.82M6.69%-1%1.22M5.6
Aug 14, 20266.88M6.75%-4%1.96M3.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded STLN

Since Nov 17, 2024, 1 member of Congress reported 0 purchases and 5 sales of STLN. The latest was a sale by Richard Blumenthal on Sep 23, 2026, reported Oct 26, 2026.

Purchases 0Sales 5

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Sep 23, 2026Richard Blumenthal (D-CT)Partial sale$1K–$15KSpouseOct 26, 2026Report
Sep 22, 2026Richard Blumenthal (D-CT)Partial sale$1K–$15KSpouseOct 26, 2026Report
Sep 22, 2026Richard Blumenthal (D-CT)Partial sale$15K–$50KSpouseOct 26, 2026Report
Sep 18, 2026Richard Blumenthal (D-CT)Partial sale$1K–$15KSpouseOct 26, 2026Report
Sep 18, 2026Richard Blumenthal (D-CT)Partial sale$15K–$50KSpouseOct 26, 2026Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Starling Oncology company events

Starling Oncology filed 15 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership, cyberattack). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Sep 2, 2026LeadershipBrad Hively notified Starling Oncology, Inc. of his decision to not stand for re-election to the Board of the Directors of the Company at its 2027 annual meeting of stockholders. Filing
  3. Aug 21, 2026AgreementStarling Oncology Management, Limited Liability Company, a wholly owned subsidiary of Starling Oncology, Inc., entered into a Credit Agreement among SOM, LLC, such other persons joined thereto as a borrower from time to time, and Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL, as lender. Filing
  4. Aug 6, 2026ResultsReleased financial results. Filing
  5. Aug 3, 2026RulesChanged its bylaws or articles. Filing
  6. Jul 7, 2026AgreementThe Oncology Institute, Inc. entered into a Credit Agreement, by and among the Company, the lenders from time to time party thereto, and Orbimed Opportunities (CA) V LLC, as the initial lender and administrative agent. Filing
  7. Jun 18, 2026VoteReported shareholder vote results. Filing
  8. May 22, 2026CyberattackThe Oncology Institute, Inc. is providing this disclosure, as a follow-up to its voluntary disclosure in Item 7.01 of a Current Report on Form 8-K filed on November 6, 2025, regarding a cybersecurity incident affecting a software service provider utilized by the Company. Filing
  9. May 7, 2026ResultsReleased financial results. Filing
  10. Mar 13, 2026AnnouncementShared information with investors. Filing
  11. Mar 12, 2026ResultsReleased financial results. Filing
  12. Feb 23, 2026LeadershipAppointment of New Director Through action taken by Unanimous Written Consent, effective February 23, 2026, the Board of Directors of The Oncology Institute, Inc. filled a vacancy on the Board by appointing Kimberly Tzoumakas to the Board. Filing
  13. Jan 12, 2026ResultsReleased financial results. Filing
  14. Jan 7, 2026LeadershipAppointment of New Director Through action taken by Unanimous Written Consent, effective January 2, 2026, the Board of Directors of The Oncology Institute, Inc. filled a vacancy on the Board by appointing Mark D. Stolper to the Board. Filing
  15. Dec 1, 2025LeadershipGabriel Ling resigned from the Board of Directors of The Oncology Institute, Inc., effective on December 1, 2025. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Starling Oncology financials

Famous investors that hold STLN

5 of the 50 well-known investors we track reported holding STLN in their latest 13F filing. The largest position is Jim Simons's, worth $7.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20261.18M$7.4M0.0%-14%
Ken Griffin · Citadel AdvisorsQ3 2026992,853$6.3M0.0%+11%
Israel Englander · Millennium ManagementQ3 2026625,522$4M0.0%+546%
Steve Cohen · Point72 Asset ManagementQ3 2026411,629$2.6M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 2026111,271$703K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named STLN in the last 120 days.

FiledHolderFormStake
Nov 13, 2026Chernett Jorey13G/A5.6%
Nov 13, 2026Chernett Jorey13G/A5.6%

Questions about Starling Oncology, Inc. (STLN) stock

Are STLN insiders buying or selling?

In the last 12 months, STLN insiders reported 17 open-market purchases worth $2.9M and 12 sales worth $14.2M. The latest trade was on Nov 9, 2026. See every trade.

What is the short interest in STLN?

As of Oct 30, 2026, 6.84M STLN shares were sold short, 6.7% of the shares outstanding, up 4.7% from the report before. At the average daily volume of 1.26M shares, buying them all back would take about 5.4 trading days (days to cover). See the history.

Have members of Congress traded STLN?

Yes. 1 member of Congress reported 0 purchases and 5 sales of STLN since Nov 17, 2024. The latest was reported on Oct 26, 2026. See the trades.

Which famous investors hold STLN?

5 of the 50 well-known investors we track reported STLN in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $7.4M. See all holders.

Executive pay

Starling Oncology's chief executive was paid a total of $1.9M for the year ended Dec 31, 2025, up 73% from $1.1M the year before. In the last 12 months, Starling Oncology's executives and directors bought no stock on the open market and sold $2.8M.

Chief executive, total pay$1.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$8MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$755KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.